The current NAUTIKA1 trial involving the neoadjuvant treatment of alectinib is enrolling patients with resectable stage II, IIIA, or selective IIIB (T3N2 only) ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.